Human Ang-Ⅱ(Angiotensin Ⅱ) ELISA Kit (E-EL-H0326)

This ELISA kit uses the Competitive-ELISA principle. The micro ELISA plate provided in this kit has been pre-coated with Human Ang-Ⅱ. During the reaction, Human Ang-Ⅱ in the sample or standard competes with a fixed amount of Human Ang-Ⅱ on the solid phase supporter for sites on the Biotinylated Detection Ab specific to Human Ang-Ⅱ. Excess conjugate and unbound sample or standard are washed away, and Avidin-Horseradish Peroxidase (HRP) conjugate are added to each micro plate well and incubated. Then a TMB substrate solution is added to each well. The enzyme-substrate reaction is terminated by the addition of stop solution and the color turns from blue to yellow. The optical density (OD) is measured spectrophotometrically at a wavelength of 450 nm ± 2 nm. The concentration of Human Ang-Ⅱ in tested samples can be calculated by comparing the OD of the samples to the standard curve.

Angiotensin II (Ang-II) is the principal effector peptide of the renin-angiotensin system. This octapeptide is generated from liver-derived angiotensinogen by the sequential action of renin, which releases the decapeptide angiotensin I, and angiotensin-converting enzyme, which acts mainly in the lung and vascular endothelium. Ang-II is degraded rapidly and functions both as a circulating hormone and as a locally produced tissue peptide, becoming activated when renal perfusion falls. Ang-II acts chiefly through the AT1 receptor, with a lesser contribution from AT2, and is a potent vasoconstrictor that also increases myocardial contractility, renal sodium retention, aldosterone secretion, sympathetic outflow, inflammation, fibrosis and oxidative stress. In the adrenal cortex it stimulates aldosterone release, and in the kidney it constricts efferent arterioles and enhances sodium reabsorption. The AT2 receptor and the Ang-(1-7)/Mas axis partly antagonize these effects, and their balance determines the net outcome. Excessive Ang-II activity contributes to hypertension, heart failure, chronic kidney disease and atherosclerosis, and its quantification assesses renin-angiotensin system activity. As the target of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers, accurate measurement supports hypertension research and monitoring of renin-system-directed therapy that has transformed cardiorenal management, and assists individualized treatment.